{
  "abstract": "Objectives The objective of this study was to assess real-world clinical outcomes, treatment responses, and safety of anifrolumab in patients with systemic lupus erythematosus (SLE).Methods We are reporting the clinical profiles, treatment responses, and safety outcomes of SLE patients receiving anifrolumab in routine clinical practice. We retrospectively reviewed 7 female patients fulfilling the 2019 EULAR/ACR classification criteria for SLE, treated with anifrolumab 300 mg intravenously every 4 weeks for at least 6 months, in combination with immunosuppressants and/or antimalarials and corticosteroids. Demographics, baseline disease characteristics, SELENA-SLEDAI scores, anti-dsDNA antibodies, complement levels, corticosteroid doses, and adverse events were recorded at treatment initiation and during the most recent follow-up.Results Mean age was 35.1 years (range 27–45) and mean disease duration was 9.4 years. Cumulative organ involvement at anifrolumab initiation included cutaneous (100%), musculoskeletal (85.7%), hematologic (71.4%) and immunologic (100%). Mean SELENA-SLEDAI score decreased from 9.7 (6–16) at baseline to 5.1 (2–14) at the most recent follow-up. Three patients achieved a major clinical response (>4-point reduction and/or anti-dsDNA negativization), two achieved a partial response (1–3-point reduction), one had stable disease, and in one patient treatment was held due to a neurological flare (right pyramidal syndrome and expressive aphasia with short-term memory impairment). Mean prednisone-equivalent dose declined from 10.9 mg/day to 4.8 mg/day in patients completing at least 6 months of therapy. No serious adverse events were reported; minor events (night sweats, mild pruritus) were transient.Conclusions In this small real-world cohort, anifrolumab was associated with clinically meaningful improvements in disease activity in most patients, alongside corticosteroid-sparing effects and good short-term tolerability. The occurrence of a neurological flare in one patient highlights the importance of close clinical and serologic monitoring during therapy. These findings support the use of anifrolumab in active SLE refractory to conventional treatment.",
  "authors": [
    {
      "affiliations": [
        "Clinical Rehabilitation Hospital, Rheumatology 2 Department, Iasi, Romania"
      ],
      "name": "Diana-Elena Cosau"
    },
    {
      "affiliations": [
        "Clinical Rehabilitation Hospital, Rheumatology 2 Department, Iasi, Romania",
        "Grigore T. Popa, University of Medicine and Pharmacy, Department of Rheumatology, Iasi, Romania"
      ],
      "name": "Mara Russu"
    },
    {
      "affiliations": [
        "Grigore T. Popa, University of Medicine and Pharmacy, Department of Physiology, Iasi, Romania"
      ],
      "name": "Lacramioara Serban"
    },
    {
      "affiliations": [
        "Clinical Rehabilitation Hospital, Rheumatology 2 Department, Iasi, Romania",
        "Grigore T. Popa, University of Medicine and Pharmacy, Department of Rheumatology, Iasi, Romania"
      ],
      "name": "Codrina Ancuta"
    }
  ],
  "title": "PO:11:299 Clinical outcomes with anifrolumab in systemic lupus erythematosus: real-world case experience",
  "uid": "513e136a-eb9d-584a-b651-058f04ab3560"
}